US 11,896,605 B2
Composition comprising HMSs/HMOs and use thereof
Louise Kristine Vigsnæs, Copenhagen NV (DK); Bruce McConnell, La Tour de Peilz (CH); and Emma Elison, Hjärup (SE)
Assigned to Glycom A/S, Hørsholm (DK)
Filed by Glycom A/S, Hørsholm (DK)
Filed on Jun. 21, 2021, as Appl. No. 17/353,749.
Application 17/353,749 is a continuation of application No. 15/906,911, filed on Feb. 27, 2018, granted, now 11,040,050.
Application 15/906,911 is a continuation in part of application No. 15/147,115, filed on May 5, 2016, abandoned.
Application 15/147,115 is a continuation in part of application No. 15/034,593, abandoned, previously published as PCT/DK2015/050332, filed on Oct. 29, 2015.
Claims priority of application No. PA201470663 (DK), filed on Oct. 29, 2014.
Prior Publication US 2021/0386766 A1, Dec. 16, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/702 (2006.01); A61K 31/706 (2006.01); A61P 1/00 (2006.01); A61K 31/7016 (2006.01)
CPC A61K 31/702 (2013.01) [A61K 31/7016 (2013.01); A61P 1/00 (2018.01)] 13 Claims
 
1. A method for reducing mast cell mediated visceral hypersensitivity and/or pain in a non-infant human, the method comprising:
selecting an effective amount of one or more neutral human milk oligosaccharides (HMOs) selected from the group consisting of 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), and combinations thereof, the amount effective for increasing a relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human; and
increasing the relative abundance of Bifidobacterium adolescentis in the gastrointestinal microbiota of the non-infant human and reducing the mast cell mediated visceral hypersensitivity and/or pain by administering to the non-infant human a daily dose of from about 3 g to about 10 g of the one or more HMOs.